News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Continue Reading Previous Aleafia Health to Announce Fiscal Year 2022 Fifth Quarter and Year End Results – UpdateNext Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Related Stories News Buy International Homes at the Global Property Expo, Singapore News Dr. Wonder Clinic Celebrates Major Milestone in Global Oral Health Advocacy with New Prevention Program News my mimi Strengthens Menstrual Education with Enhanced Learning Platform News Interact Direct Holdings Limited Files Late Early Warning Report News Universal Digital Acquires 10 Bitcoin in First Treasury Allocation News Gorilla Provides Business Updates
